Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

David Devos , Caroline Moreau , Jean Christophe Devedjian , David Devos , Caroline Moreau , Jean Christophe Devedjian , Jérôme Kluza , Maud Pétrault , Charlotte Laloux , Aurélie Jonneaux , Gilles Ryckewaert , Guillaume Garçon , Nathalie Rouaix , Alain Duhamel , P. Jissendi , Kathy Dujardin , F. Auger , Laura Ravasi , Lucie Hopes , Guillaume Grolez , Wance Firdaus , Bernard Sablonnière , Isabelle Strubi-Vuillaume , Noël Zahr , A. Destée , Jean‐Christophe Corvol , Dominik Pöltl , Marcel Leist , Christian Rosé , Luc Defebvre , Philippe Marchetti , Z. Ioav Cabantchik , Régis Bordet
2013 Antioxidants and Redox Signaling 593 citations

Abstract

The therapeutic features of a chelation modality established in translational models and in pilot clinical trials warrant comprehensive evaluation of symptomatic and/or disease-modifying potential of chelation in PD.

Keywords

DeferiproneSubstantia nigraOxidative stressDopamineParkinson's diseaseStriatumDeferasiroxMedicineInternal medicinePlaceboDeferoxamineClinical trialDiseasePathologyGastroenterologyPharmacology

Affiliated Institutions

Related Publications

Parkinson disease

Roberta Balestrino , Anthony H.V. Schapira

Parkinson disease (PD) is the most common neurodegenerative movement disorder. In Europe, prevalence and incidence rates for PD are estimated at approximately 108–257/100 000 an...

2019 European Journal of Neurology 1340 citations

Publication Info

Year
2013
Type
article
Volume
21
Issue
2
Pages
195-210
Citations
593
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

593
OpenAlex

Cite This

David Devos, Caroline Moreau, Jean Christophe Devedjian et al. (2013). Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease. Antioxidants and Redox Signaling , 21 (2) , 195-210. https://doi.org/10.1089/ars.2013.5593

Identifiers

DOI
10.1089/ars.2013.5593